PreveCeutical Medical Inc (PRVCF)

[NetworkNewsWire]

NetworkNewsAudio – Promising New Approaches in Pain Management


Related Editorial
Pain is a wide-ranging complex medical condition that can be both physically debilitating and mentally destabilizing. Whether acute or chronic, caused by disease, trauma or neural damage, current pain therapeutics primarily rely on a variety of opioid-based pharmacological therapies that have ignited a severe public health crisis. The rampant dependency and abuse of opioid-based drugs has triggered a global quest for effective opioid free medications. Societal demands and sheer market size have bio-pharmaceutical companies searching for solutions to address the critical need for new ways to successfully treat pain. Establishing a new paradigm in pain management solutions, PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) has undertaken a novel approach in the development of non-addictive analgesics by engineering peptides into efficient pain blockers, eliminating highly addictive opioids. Other companies in the hunt for pain management solutions include AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Nektar Therapeutics (NASDAQ: NKTR), Flexion Therapeutics, Inc. (NASDAQ: FLXN) and Cara Therapeutics (NASDAQ: CARA).

To hear the NetworkNewsAudio version, visit http://nnw.fm/MC79a

To view the full editorial, visit http://nnw.fm/v7nPC

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com